Catastrophic antiphospholipid syndrome market seen reaching $6.8 billion by 2030

The catastrophic antiphospholipid syndrome market is projected to expand from $4.6 billion in 2026 to $6.8 billion by 2030, according to a new industry report. Growth is tied to better diagnosis, broader treatment use and rising clinical research in a rare autoimmune disease that can cause rapid, life-threatening blood clots.

Why it matters: - Catastrophic antiphospholipid syndrome, or CAPS, is a rare autoimmune disease that can trigger rapid blood clotting and multiple organ failure. - Market growth reflects wider use of diagnostics, intensive care and therapies that can help patients survive a condition that requires immediate treatment. - The report points to growing investment in rare disease research and precision therapies as a sign of continued demand through 2030.

What happened: - The Business Research Company said the catastrophic antiphospholipid syndrome market rose from $4.16 billion in 2025 to an expected $4.6 billion in 2026. - The report projects the market will reach $6.8 billion by 2030, implying a 10.3% compound annual growth rate over the forecast period. - The report was released Nov. 10, 2026, and covers market size, trends and forecasts through 2035. - Download a free sample of the report.

The details: - The report says recent growth was driven by better detection of antiphospholipid antibodies, broader anticoagulant use, more documentation of rare autoimmune disorders, expanded intensive care capacity and higher use of plasmapheresis in critical care. - Future growth is expected to come from complement inhibitor research, demand for biologic treatments, more rare-disease clinical trials, better precision diagnostics and collaboration among specialty care centers. - Key trends include precision immunotherapy, combination treatment regimens, early diagnosis, greater clinical awareness of rare autoimmune diseases and targeted biologic therapies. - CAPS is triggered by antiphospholipid antibodies and is typically treated with anticoagulants, corticosteroids and immunosuppressive drugs. - A growing prevalence of autoimmune diseases is adding to demand because autoimmune conditions can promote the antibodies linked to CAPS. - The Crohn's and Colitis Foundation of Canada said in June 2023 that 322,600 Canadians were living with inflammatory bowel disease in 2023, with that number expected to rise to 470,000 by 2035. - The same source projected annual new cases in Canada would rise from 11,000 to 14,000. - Rising healthcare spending is also supporting the market by improving access to diagnostics, intensive care and treatments. - The Centers for Medicare & Medicaid Services reported that U.S. national health expenditures rose 7.5% in 2023 to $4.9 trillion, equal to $14,570 per person and 17.6% of GDP. - Medicare spending rose 8.1% to $1,029.8 billion, or 21% of total national healthcare expenditures. - More clinical trials are also accelerating development of new CAPS treatments. - The Association of the British Pharmaceutical Industry said UK pharmaceutical clinical trials increased from 411 in 2022 to 426 in 2023. - View the full market report.

Between the lines: - The market is still small compared with broader therapy categories, but rare-disease demand can expand quickly when diagnosis improves and care pathways become more standardized. - The report’s emphasis on biologics, precision diagnostics and combination therapy suggests the market is shifting toward more specialized, higher-value care. - North America held the largest market share in 2025, while Asia-Pacific is expected to grow fastest during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

What's next: - Clinical trial activity, specialty-center collaboration and precision diagnostic tools are likely to shape the next phase of market growth. - Adoption of targeted biologics and complement inhibitor research could influence treatment standards if development progress continues. - The report’s broader forecast through 2035 suggests investors and providers will continue tracking rare autoimmune disease demand across major regions.

The bottom line: - CAPS remains a rare but high-need market, and the combination of better diagnosis, more research and rising healthcare spending is expected to keep growth above 10% through 2030.